The new national Precision Omics Initiative Sweden (PROMISE) aims to generate and integrate extensive molecular data to create a model for precision medicine implementation for Sweden.
The boom in interventional radiology procedures has enabled great strides in ischemic stroke management. But while a myriad of techniques are available, the challenge remains in choosing the most appropriate thrombectomy treatment on the spot, according to Jordi Blasco Andaluz, a neuroradiologist at Hospital Clinic Barcelona. The new ROSSETTI registry is designed to change this.
Certain gene alterations can serve as a prognostic and predictive biomarker for prostate cancer. Now, researchers confirm the feasibility of using NGS on this marker for precise patient stratification and treatment selection.
Researchers developed a smart patch capable of real-time biometric signal monitoring and drug delivery. Potential applications include glucose management, pain relief, and chronic disease treatment.
A new personalised oncology platform has been tested to detect circulating tumour DNA (ctDNA) in patients with lung adenocarcinoma before surgery, to predict their risk of cancer relapse.
The current rise in antibiotic resistance is once again sparking interest in phage therapy. Now, scientists developed a new tool that recommends the best possible phage cocktail for a given patient.
New research has shown that using artificial intelligence (AI) can improve how urinary tract infections (UTIs) are treated, and help to address antimicrobial resistance (AMR).
A bit more mucus in the nose, a little less air in the gut: Even small changes can be important when planning proton therapy against cancer. A new workflow allows for an adapted irradiation every day.
A US-Swiss team leverages AI and molecular simulations to uncover new pathways for precision cancer treatments, paving the way for more effective, personalized therapies.
Can a look at a patient's DNA predict progress of their colorectal cancer? Findings from a new study could lead to improved possibilities for individualised therapies.
The pace of artificial intelligence (AI) adoption in personalised medicine is unsettling for great parts of the public. A new survey reflects the worried state of mind in the UK.
Using genomic sequencing data, researchers have created personalised simulations of individual patients that can quantify the impact of genetic mutations on cancer cell behaviour.
Using advanced technology from the automotive and manufacturing industries, researchers are driving medical advancement to create ‘personalised’ hip replacements.
Researchers have developed a cutting-edge method for fabrication of customised pharmaceutical tablets with tailored drug release profiles, ensuring more precise and effective treatment options.
Generalist Medical Artificial Intelligence (GMAI) models pose a significant challenge to current regulatory frameworks. Experts discuss how regulation of these models could work in the future.
Researchers discovered three distinct immunological endophenotypes of multiple sclerosis, defined by specific blood immune signatures. This opens new avenues for personalized treatment strategies.
In a breakthrough for personalised oncology, scientists have developed and demonstrated a novel platform that can significantly reduce the time needed to determine the efficacy of anti-cancer drugs.
AI technology holds promise for personalised cancer therapies. However, rigid and slow approval requirements impede its introduction, say experts – and point out how this might be changed.
An 'encyclopaedia' of protein alterations in soft tissue sarcomas could open the door to a new era of understanding and treatment for this group of rare cancers.
